Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

Core Viewpoint - Soligenix, Inc. is urging eligible stockholders to vote their shares at the upcoming reconvened meeting on May 30, 2024, emphasizing the importance of shareholder participation in corporate governance [1][2]. Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs [5]. - The company is advancing its Specialized BioTherapeutics segment, which includes HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and is seeking regulatory approvals for potential worldwide commercialization [5]. - Other development programs include SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [5]. Public Health Solutions - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine candidate, and vaccines targeting filoviruses and COVID-19 [6][7]. - The vaccine programs utilize the proprietary ThermoVax® technology and have received government funding from agencies such as NIAID, DTRA, and BARDA [7]. Voting Information - Eligible stockholders can vote by contacting the company's proxy solicitor, Alliance Advisors, and must have held shares as of the record date, April 10, 2024 [2]. - Stockholders who sold their shares after the record date are still encouraged to vote [2]. Proxy Materials - The company filed a definitive proxy statement and proxy card with the SEC on April 29, 2024, and stockholders are urged to read these documents for important information regarding the Annual Meeting [3][4].